[Unasyn in severe hospital infections].
A total 16 patients with moderate and serious surgical and urogenital infections were treated intravenously with the Unasyn IM/IV inj., combination of ampicillin and sulbactam, which is a beta-lactamase inhibitor. In this combination, sulbactam saves the ampicillin against the effects of beta-lactamases and extends the susceptibility to ampicillin of previously ampicillin-resistant strains. Clinical cure was observed in 69% of the patients, improvement in 19%, and failure in 12%. Microbiological elimination was proved in 50% of the patients, persistence in 6%, a in the rest of the patients (44%) were microbiological response unevaluable. The evaluation of subjective and objective tolerance of Unasyn IM/IV inj. was excellent. It follows from this study that the combination of ampicillin with sulbactam can be considered an effective and safe treatment of nosocomial infections, especially in the departments with an increasing rate of ampicillin-resistant strains due to production of the beta-lactamases.
Sechser
T
T
I. interní výzkumná základna, Institutu klinické a experimentální medicíny, Praha.
Hatala
M
M
Svácek
J
J
Modr
Z
Z
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013407:Sulbactam / Q000627:therapeutic use*; D013530:Surgical Wound Infection / Q000188:drug therapy*
C035444:sultamicillin; D000667:Ampicillin; D013407:Sulbactam
Unasyn u tĕzkých nemocnicních infekcí.